For the DoxyPEP protocol itself — dosing, timing, the dairy rule, the esophagus risk, sun sensitivity, and the decision matrix for when to use it — read DoxyPEP: The Morning After Pill for Bacteria first. This guide covers the US-specific picture: why the US went further than Europe on this, how to access it, and what it costs.

The Evidence Behind the US Position

The landmark DoxyPEP studies showed compelling results for MSM and transgender women:

  • 87% reduction in syphilis cases
  • 88% reduction in chlamydia cases
  • 55% reduction in gonorrhea cases

In 2023, the US CDC formally endorsed DoxyPEP — making it official federal guidance for gay and bisexual men and transgender women who have had a bacterial STI in the past year or who are at high behavioural risk. This puts the US significantly ahead of most of Europe, where antibiotic stewardship concerns have kept regulators cautious.

Why the US Went Further Than Europe

European health authorities — particularly the ECDC — have resisted official DoxyPEP guidance, primarily citing antibiotic resistance concerns. The US position reflects a calculation that the syphilis crisis in MSM communities (rates up 50%+ year-over-year in many cities) represents a more immediate harm than the theoretical resistance risk when use is targeted to high-risk individuals.

Both positions contain legitimate arguments. The practical difference: in the US, you can walk into an LGBTQ+ health center and ask for DoxyPEP, and most will prescribe it. In most of Europe, you need to find a sympathetic clinician willing to go off-guideline.

Who Should Consider It

The CDC's guidance targets:

  • MSM or transgender women who have been diagnosed with gonorrhoea, chlamydia, or syphilis in the past 12 months
  • MSM or transgender women who assess themselves at high risk based on sexual behaviour and the number of partners

If you're already on PrEP and testing every three months, you're exactly the population this is designed for. DoxyPEP sits alongside PrEP — it doesn't replace it, and it doesn't replace regular testing.

Where to Get It in the United States

LGBTQ+ health centers: The most straightforward route. Most experienced LGBTQ+ health centers have incorporated DoxyPEP into their standard PrEP clinic protocols since 2023–2024. Callen-Lorde, Fenway Health, Howard Brown, Los Angeles LGBT Center, Whitman-Walker, and similar centres are prescribing routinely.

Sexual health clinics: Most public health department sexual health clinics in major cities now offer DoxyPEP. Availability in smaller cities and rural areas is less consistent.

Telehealth: Services including MISTR, Folx Health, and Planned Parenthood Direct can prescribe DoxyPEP in most states alongside PrEP. This is the fastest route if you're not near an LGBTQ+ health center.

Primary care GP: Hit and miss. Some GPs are up to date with the CDC guidance; others aren't aware of DoxyPEP or are reluctant to prescribe it. Having the CDC guidance document on hand helps. The general section has guidance on navigating reluctant providers — see Finding an LGBTQ+-Affirming Doctor.

Cost

Doxycycline is cheap and off-patent. A 10-tablet supply (five doses, as each dose is 200mg = two 100mg tablets) costs:

  • With insurance: $0–$10 typically — doxycycline is on virtually every generic formulary
  • GoodRx without insurance: $10–$30 for a supply sufficient for several months of use
  • Without insurance or GoodRx: ~$20–40 at most pharmacies

This is one of the most accessible medications in US sexual health. Cost is rarely the barrier.

What DoxyPEP Does NOT Do

  • Does NOT prevent HIV — that's PrEP's function.
  • Does NOT protect against HPV or Hepatitis — vaccines cover those.
  • Does NOT replace regular testing — quarterly three-site testing is still required. DoxyPEP may actually reduce the yield of tests over time (fewer infections to find), but you still need to test.
  • Does NOT prevent future infections — it only reduces risk after a specific exposure.

The Resistance Question

The antibiotic resistance concern is real, not dismissible. Doxycycline resistance in gonorrhea is already observed in some settings. Responsible DoxyPEP use means:

  • Targeting it to genuinely high-risk situations, not using it after every sexual encounter as a routine
  • Continuing quarterly testing — this is how emerging resistance is caught
  • Discussing with your provider whether your risk profile justifies ongoing use

The CDC guidance is population-level; your individual decision should account for your specific risk level.

Related: